Profectus gains $6.25M in grants

Profectus BioSciences has received $6.25 million in National Institute of Allergy and Infectious Diseases grants, including $2.9 million in Small Business Innovative Research grants. The company's adjuvant profile focuses on harnessing the body's immune system to fight off viruses and cancers more effectively. Earlier this week, the company received an additional $4.4 million for its HIV vaccine. Profectus release

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.